ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013
Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Trial
- Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.Molecular oncology · 2014Trial
- Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer.Cell reports · 2021Article
- Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.Frontiers in oncology · 2019Review
- The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.The oncologist · 2015Review
- HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.Gynecologic oncology · 2015Article
- Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications.Therapeutic advances in medical oncology · 2014Review
- Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.Journal of the National Cancer Institute · 2014Article
- Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology.Medical oncology (Northwood, London, England) · 2014Article
- Improving the efficacy of chemoradiation with targeted agents.Cancer discovery · 2014Review
- Circulating tumor cells in breast cancer.Journal of carcinogenesis · 2014Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
23569319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.